文献速递冠心病血脂与心血管预防

重组人载脂蛋白A-I对急性心梗幸存者复发性缺血事件的影响

Effect of Reconstituted Human Apolipoprotein A-I on Recurrent Ischemic Events in Survivors of Acute MI.
PubMed 文献 · J Am Coll Cardiol · 2024-04-06

AEGIS-II试验将18219例高危急性心梗患者随机分配至每周4次静脉输注6g CSL112(人apoA-I制剂)或安慰剂,探索性分析显示CSL112组心血管死亡和1型心梗复合终点发生率数值上降低(180天HR 0.86,95%CI 0.74-0.99,P=0.048),但主要研究终点未显著降低,需进一步前瞻性数据确认。

要点

  • CSL112未显著降低主要研究终点,但心血管死亡和心梗发生率数值上较低。
  • 180天时心血管死亡或1型心梗复合终点HR 0.86(95%CI 0.74-0.99,P=0.048)。
  • 获益主要见于1型心梗和支架血栓相关4b型心梗,机制可能涉及胆固醇流出。

核心结论

  • CSL112未显著降低主要研究终点,但接受CSL112输注的患者心血管死亡和心梗、1型心梗及支架血栓相关心梗发生率数值上低于安慰剂组。

研究设计与样本

  • AEGIS-II为国际、多中心、随机、双盲、安慰剂对照试验,共随机18219例高危急性心梗患者。
  • 患者接受每周4次静脉输注6g CSL112(人apoA-I制剂)或安慰剂。

主要发现

  • 心血管死亡和1型心梗复合终点发生率在CSL112组整个研究期间降低11%至16%(90天HR 0.84,95%CI 0.7-1.0,P=0.056;180天HR 0.86,95%CI 0.74-0.99,P=0.048;365天HR 0.89,95%CI 0.79-1.01,P=0.07)。
  • 心血管死亡或任何心梗发生率在CSL112组数值上较低(90天HR 0.92,95%CI 0.80-1.05;180天HR 0.89,95%CI 0.79-0.996;365天HR 0.91,95%CI 0.83-1.01)。
  • CSL112对心梗的影响主要见于1型心梗和4b型心梗(支架血栓所致心梗)。

临床怎么用

  • 对于高危急性心梗幸存者,CSL112可能通过增强胆固醇流出来减少后续斑块破裂事件,但当前证据尚不足以支持常规临床应用。

局限性

  • 本研究为探索性分析,主要研究终点未显著降低,观察到的获益需进一步前瞻性数据确认。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The AEGIS-II trial hypothesized that CSL112, an intravenous formulation of human apoA-I, would lower the risk of plaque disruption, decreasing the risk of recurrent events such as myocardial infarction (MI) among high-risk patients with MI. OBJECTIVES: This exploratory analysis evaluates the effect of CSL112 therapy on the incidence of cardiovascular (CV) death and recurrent MI. METHODS: The AEGIS-II trial was an international, multicenter, randomized, double-blind, placebo-controlled trial that randomized 18,219 high-risk acute MI patients to 4 weekly infusions of apoA-I (6 g CSL112) or placebo. RESULTS: The incidence of the composite of CV death and type 1 MI was 11% to 16% lower in the CSL112 group over the study period (HR: 0.84; 95% CI: 0.7-1.0; P = 0.056 at day 90; HR: 0.86; 95% CI: 0.74-0.99; P = 0.048 at day 180; and HR: 0.89; 95% CI: 0.79-1.01; P = 0.07 at day 365). Similarly, the incidence of CV death or any MI was numerically lower in CSL112-treated patients throughout the follow-up period (HR: 0.92; 95% CI: 0.80-1.05 at day 90, HR: 0.89; 95% CI: 0.79-0.996 at day 180, HR: 0.91; 95% CI: 0.83-1.01 at day 365). The effect of CSL112 treatment on MI was predominantly observed for type 1 MI and type 4b (MI due to stent thrombosis). CONCLUSIONS: Although CSL112 did not significantly reduce the occurrence of the primary study endpoints, patients treated with CSL112 infusions had numerically lower rates of CV death and MI, type-1 MI, and stent thrombosis-related MI compared with placebo. These findings could suggest a role of apoA-I in reducing subsequent plaque disruption events via enhanced cholesterol efflux. Further prospective data would be needed to confirm these observations.

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Povsic TJ, Korjian S, Bahit MC, et al. Effect of Reconstituted Human Apolipoprotein A-I on Recurrent Ischemic Events in Survivors of Acute MI. J Am Coll Cardiol. 2024. PMID: 38588930. doi:10.1016/j.jacc.2024.03.396

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。